Evidence map›Paper›PMID 40476283›Full record

ArticleJournal of radiosurgery and SBRT2025

Stereotactic ablative radiation therapy for extracranial metastases from malignant melanoma: An international multi-institutional analysis.

Raj Singh, Sophia Bishop, Jan Jenkins, Joanne Davis, Eric J Lehrer, Sujith Baliga, Joshua D Palmer, John A Vargo, Christopher M McLaughlin, Emile Gogineni and 1 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of radiosurgery and SBRT, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Raj SinghOhio State University Comprehensive Cancer Center, Department of Radiation Oncology, Columbus, OH, USA.
Sophia BishopRadiosurgery Society, San Jose, CA, USA.
Jan JenkinsRadiosurgery Society, San Jose, CA, USA.
Joanne DavisRadiosurgery Society, San Jose, CA, USA.
Eric J LehrerMayo Clinic, Department of Radiation Oncology, Rochester, MN, USA.
Sujith BaligaOhio State University Comprehensive Cancer Center, Department of Radiation Oncology, Columbus, OH, USA.
Joshua D PalmerOhio State University Comprehensive Cancer Center, Department of Radiation Oncology, Columbus, OH, USA.
John A VargoUniversity of Virginia Health System, Department of Radiation Oncology, Charlottesville, VA, USA.
Christopher M McLaughlinUniversity of Pittsburgh Medical Center, Department of Radiation Oncology, Pittsburgh, PA, USA.
Emile GogineniOhio State University Comprehensive Cancer Center, Department of Radiation Oncology, Columbus, OH, USA.
Sanjeev SharmaSt Mary's Medical Center, Department of Radiation Oncology, Huntington, WV, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To report on local control (LC), toxicity, and overall survival (OS) following stereotactic ablative radiation therapy (SABR) for extracranial metastases from malignant melanoma. Methods: The RSSearch Results: There were 45 patients with 52 extracranial melanoma metastases treated with SABR. One- and 2-year LC rates were both 85.3% (95% CI: 67.9-93.7%) following SABR. On UVA, BED10 < 60 Gy was associated with poorer 1-year and 2-year LC (96% vs. 61.9%), which remained significant on MVA (hazard ratio [HR] = 7.06; p = 0.03). On UVA, pulmonary vs. non-pulmonary metastases were correlated with 1-year OS (84.5% vs. 57.4%; p = 0.05) and non-spinal vs. spinal metastases (74.3% vs. 56.3%; p = 0.02), though neither were significant on MVA. The incidence of treatment-related toxicity was 18.9%, all Grade 1-2. Conclusion: We recommend dose/fractionation schedules that meet or exceed BED10 ≥ 60 Gy when treating extracranial melanoma metastases with SABR.

Indexed as

local controlmelanomametastasesoverall survivalSABRtoxicity

Identifiers

PMID40476283
PMCPMC12136682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.